Business

Abbott Laboratories (NYSE:ABT) Has 19 Percent Upside Potential

Abbott Laboratories (NYSE:ABT) shares traded 0.28% during the most recent session the stock exchanged hands 6.17M shares versus average trading capacity of 6.39M shares, yielding a market cap of $75.06B. Wall Street analysts covering the stock are projecting that the stock will reach $48.27 within the next 52-weeks. The mean target projections are based on 11 opinions, the mean target was last revised on 04/21/17.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Abbott Laboratories (NYSE:ABT) high price target of $52.00 and with a conservative view have low price target of $43.00 with a standard deviation of $1.42. If seeing target price from optimistic overview then it has a 19 percent upside potential from the latest closing price of $43.60.

Abbott Laboratories (NYSE:ABT) “Reiterated” by Barclays in a research note issued to investors on Apr-20-17 from Overweight from $50 to $52.

Additionally on Mar-01-17 Abbott Laboratories (NYSE:ABT) was “Reiterated” by RBC Capital Mkts as Outperform from $46 to $50 and on Jan-26-17 the stock was “Reiterated” by RBC Capital Mkts as Outperform at $48 to $46. Furthermore on Jul-21-16 the stock was “Reiterated” by Barclays as Overweight from $48 to $50.

On the other hand the company has Relative Strength Index (RSI 14) of 46.00 along with Average True Range (ATR 14) of 0.52, Consequently Abbott Laboratories (NYSE:ABT) weekly and monthly volatility is 0.83%, 1.23% respectively. The company’s beta value is at 1.43.

In terms of Buy, Sell or Hold recommendations, Abbott Laboratories (NYSE:ABT) has analysts’ mean recommendation of 1.90. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

Analysts who have weighed in on projected earnings growth are expecting that Abbott Laboratories (NYSE:ABT) will report earnings of $0.6 for the current quarter, however the company’s high EPS estimates are $0.61 and low estimates are $0.6. However the company reported $0.55 earnings per share for the same quarter during last year.

Previously Abbott Laboratories (NYSE:ABT) reported $0.48 earnings per share (EPS) for the quarter on 4/19/2017 Before Market Open, beating the consensus estimate of $0.43 by $0.05. The company posted an earnings surprise of 11.63%.

While considering growth estimates of the company, it has next quarter growth estimates of 11.90% whereas during current quarter it has 9.10% estimations over growth, comparing to the estimations of 12.30% during current year and 12.10% for next year. Past 5 years growth of Abbott Laboratories (NYSE:ABT) observed at -12.30%, looking forward for the next 5 years it has a strong prediction of 11.22% over growth.

Abbott Laboratories (NYSE:ABT) revenue estimates for the current quarter are $6.63B according to 14 number of analysts, for the current quarter the company has high revenue estimates of $6.72B in contradiction of low revenue estimates of $6.52B. For the current year the company’s revenue estimates are $26.37B compared to low analyst estimates of $26.06B and high estimates of $26.62B according 16 number of analysts.

Currently Abbott Laboratories (NYSE:ABT) shares owned by insiders are 0.70%, whereas shares owned by institutional owners are 65.80%. However the six-month change in the insider ownership was recorded 1.67%, as well as three-month change in the institutional ownership was recorded -0.04%.

Abbott Laboratories (NYSE:ABT) trading -4.30% away from its 52 week high of $45.56 and +21.61% far from the stock’s low point over the past 52 weeks, which was $35.85. The stock hit its 52-week high on 03/10/17, and 52-week low on 06/27/16. The company’s trailing twelve month income is 1.39B dollars and is paying 2.43% dividend yield annually.

Abbott Laboratories (NYSE:ABT) trailing twelve month revenues are $22.30B, whereas its price to sales ratio for the same period is 3.38. Its book value per share for the most recent quarter is $13.94 while its price to book ratio for the same period is 3.13. The stock has a current PEG ratio of 4.31 where as its trailing twelve month P/E ratio is 48.39.

Previous ArticleNext Article
%d bloggers like this: